Also known as Byetta · Bydureon · Exendin-4 · AC2993
The first GLP-1 receptor agonist ever approved (Byetta, 2005) — synthetic exendin-4, a 39-residue peptide first isolated from Gila monster venom.
Research refreshed
39 residues · single-letter amino-acid sequence
Exenatide is where the GLP-1 drug class began. It is the synthetic form of exendin-4, a 39-amino-acid peptide discovered in the venom of the Gila monster (Heloderma suspectum) that activates the human GLP-1 receptor but resists the enzyme that destroys native GLP-1 in minutes. The FDA approved it as twice-daily Byetta in April 2005 for type 2 diabetes, and as once-weekly Bydureon — the same peptide in slow-release microspheres — in 2012. It has since been overtaken by longer-acting agents, but every later GLP-1 drug descends from its proof of concept.
In 1992 the endocrinologist John Eng, screening lizard venoms for bioactive peptides, isolated exendin-4 from the Gila monster. It shares only about half its sequence with human GLP-1, yet it binds and activates the same receptor — and because its second residue is glycine rather than alanine, the enzyme DPP-4 cannot clip it. A two-minute hormone became a peptide with a half-life of about 2.4 hours.
Amylin Pharmaceuticals and Eli Lilly developed the synthetic peptide as exenatide. Byetta (twice daily before meals) was approved in 2005 as the first GLP-1 receptor agonist, with modest weight loss noted from the start. The next step was a delivery solution rather than a new molecule: Bydureon encapsulates the unmodified peptide in biodegradable poly(lactide-co-glycolide) microspheres that release it over weeks, allowing once-weekly dosing without acylation or fusion — a formulation approach none of the later blockbusters took.
Its outcomes record is mixed, and worth stating plainly. EXSCEL (Holman et al., NEJM 2017) followed 14,752 adults with type 2 diabetes: weekly exenatide was non-inferior to placebo for major cardiovascular events (hazard ratio 0.91, 95% CI 0.83–1.00) but narrowly missed superiority. Interest in GLP-1 agonists for neurodegeneration began with small exenatide trials in Parkinson’s disease, but the Phase 3 Exenatide-PD3 trial (Lancet 2025) found no benefit over 96 weeks. Exenatide is a 39-residue linear peptide with no acylation, which makes it one of the more tractable incretins to synthesize.
GLP-1 receptor agonism → glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, increased satiety. A glycine at position 2 (where GLP-1 has alanine) blocks DPP-4 cleavage.
Behind every vial of Exenatide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Exenatide, specifically, is brought into being.
On paper, Exenatide is C184H282N50O60S — about 4,186.6 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Exenatide means roughly 39 coupling cycles on the synthesizer — one protected residue added at a time, which is also 39 chances for an incomplete coupling to seed a deletion impurity. At this length the growing chain is prone to aggregation on the resin, making every later cycle harder — long sequences are where small per-cycle losses compound into a messy crude. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Exenatide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of Exenatide proves itself: identity confirmed by mass spectrometry against its ~4,186.6 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Exenatide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Exenatide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Exenatide, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Exenatide is a 39-amino-acid GLP-1 receptor agonist — the synthetic version of exendin-4 — FDA-approved for type 2 diabetes as twice-daily Byetta (2005) and once-weekly Bydureon (2012). It was the first drug in the GLP-1 class.
The peptide it copies does. Exendin-4 was isolated from Gila monster venom in 1992. The drug itself is made by chemical peptide synthesis, not extracted from lizards.
Exenatide is based on a lizard peptide, has a half-life of about 2.4 hours, and reaches weekly dosing only through a slow-release microsphere formulation. Semaglutide is based on human GLP-1 and is acylated so the molecule itself lasts about a week. Semaglutide produces much larger weight and HbA1c reductions.
Modestly — typically a few kilograms in diabetes trials. It has no weight-management indication.
Small early trials suggested a possible effect, but the Phase 3 Exenatide-PD3 trial (Lancet 2025) found no benefit over placebo across 96 weeks. It is not approved for any neurological use.
Nausea is the most common, along with vomiting and diarrhea; the weekly formulation can cause injection-site nodules. Bydureon carries the class boxed warning about thyroid C-cell tumors. This page is a research reference, not medical advice.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.